Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

XTL plans to develop Dov's bicifadine for neuropathic pain

Executive Summary

Giving itself a chance to focus on other programs, Dov Pharmaceutical (CNS drug candidates) has licensed infectious disease firm XTL Biopharmaceuticals exclusive worldwide rights to Phase III bicifadine, which XTL plans to develop for neuropathic pain.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal

Related Companies

Advertisement
UsernamePublicRestriction

Register